These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 16697272)

  • 81. Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes.
    Vuppalanchi R; Teal E; Chalasani N
    Am J Med Sci; 2005 Feb; 329(2):62-5. PubMed ID: 15711421
    [TBL] [Abstract][Full Text] [Related]  

  • 82. [Serum bilirubin in an obvious healthy population (author's transl)].
    Weigl E; Bach H; Krieg D
    Med Klin; 1975 Apr; 70(15):664-9. PubMed ID: 1143167
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Hepatotoxicity fears contribute to underutilization of statin medications by primary care physicians.
    Rzouq FS; Volk ML; Hatoum HH; Talluri SK; Mummadi RR; Sood GK
    Am J Med Sci; 2010 Aug; 340(2):89-93. PubMed ID: 20588181
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Statins and hepatitis C virus infection: an old therapy with new scope.
    Rzouq F; Alahdab F; Olyaee M
    Am J Med Sci; 2014 Nov; 348(5):426-30. PubMed ID: 24805786
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Use of statins in patients with liver disease.
    Kalaitzakis E; Björnsson ES
    Minerva Gastroenterol Dietol; 2014 Mar; 60(1):15-24. PubMed ID: 24632765
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study.
    Bruckert E; Hayem G; Dejager S; Yau C; Bégaud B
    Cardiovasc Drugs Ther; 2005 Dec; 19(6):403-14. PubMed ID: 16453090
    [TBL] [Abstract][Full Text] [Related]  

  • 87. [Etiologies of a moderate and prolonged elevation of serum activity of transaminases: the end of "transaminitis"?].
    Bastie A; Capron JP
    Gastroenterol Clin Biol; 1993; 17(1):33-6. PubMed ID: 8467968
    [No Abstract]   [Full Text] [Related]  

  • 88. [Immunosuppression with 6-mercaptopurine in chronic hepatitis].
    Bauer-Hack K
    Med Welt; 1969 Feb; 8():443-6. PubMed ID: 5771348
    [No Abstract]   [Full Text] [Related]  

  • 89. Statin use and the risk of liver cancer: a population-based case–control study.
    Chiu HF; Ho SC; Chen CC; Yang CY
    Am J Gastroenterol; 2011 May; 106(5):894-8. PubMed ID: 21157439
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Compliance to recommended liver function monitoring in patients on statin therapy.
    Leaver H; Keng Lim T; Thomson P; Leaver J; Choy AM; Lang CC
    Cardiovasc Ther; 2009; 27(2):96-100. PubMed ID: 19426246
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Hepatotoxicity associated with statin use: analysis of the cases included in the Spanish Hepatotoxicity Registry.
    Perdices EV; Medina-Cáliz I; Hernando S; Ortega A; Martín-Ocaña F; Navarro JM; Peláez G; Castiella A; Hallal H; Romero-Gómez M; González-Jiménez A; Robles-Díaz M; Lucena MI; Andrade RJ
    Rev Esp Enferm Dig; 2014 Apr; 106(4):246-54. PubMed ID: 25075655
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Hepatic effects of lovastatin exposure in patients with liver disease: a retrospective cohort study.
    Avins AL; Manos MM; Ackerson L; Zhao W; Murphy R; Levin TR; Watson DJ; Hwang PM; Replogle A; Levine JG
    Drug Saf; 2008; 31(4):325-34. PubMed ID: 18366243
    [TBL] [Abstract][Full Text] [Related]  

  • 93. [Reducing of hepatotoxicity of antineoplastic chemotherapy and concomitant viral infection through control of liver metabolism: from experiment to clinical practice].
    Bogush TA; Bogush EA; Durnov LA; Syrkin AB
    Vopr Onkol; 2001; 47(6):662-71. PubMed ID: 11826485
    [No Abstract]   [Full Text] [Related]  

  • 94. The myth of statin-induced hepatotoxicity.
    Bader T
    Am J Gastroenterol; 2010 May; 105(5):978-80. PubMed ID: 20445507
    [No Abstract]   [Full Text] [Related]  

  • 95. [Biochemical characterization of viral hepatitis in humans, using and not using narcotics].
    Tomilka GS; Zhuravlev IaA; Gordinskaia NM
    Ter Arkh; 2002; 74(11):6-10. PubMed ID: 12498114
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Disulfiram use in patients with abnormal liver function test results.
    Saxon AJ; Sloan KL; Reoux J; Haver VM
    J Clin Psychiatry; 1998 Jun; 59(6):313-6. PubMed ID: 9671344
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Hepatotoxicity of Statins as Determined by Serum Alanine Aminotransferase in a Pediatric Cohort With Dyslipidemia.
    Desai NK; Mendelson MM; Baker A; Ryan HH; Griggs S; Boghani M; Yellen E; Buckley L; Gillman MW; Zachariah JP; Graham D; Jonas MM; de Ferranti SD
    J Pediatr Gastroenterol Nutr; 2019 Feb; 68(2):175-181. PubMed ID: 30334928
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity.
    Gearhart MO
    Ann Pharmacother; 1994 Oct; 28(10):1177-81. PubMed ID: 7841574
    [TBL] [Abstract][Full Text] [Related]  

  • 99. [Clinicomorphological changes of liver in atherogenic dyslipidemia and after treatment with statins].
    Lazebnik LB; Zvenigorodskaia LA; Morozov IA; Shepeleva SD
    Ter Arkh; 2003; 75(8):51-5. PubMed ID: 14520852
    [TBL] [Abstract][Full Text] [Related]  

  • 100. [Primary evaluation of the therapeutic effect of non-bioartificial liver support system on severe hepatitis].
    Niu R; Wang Y; Wang Y; Liu J; Liu G; Li J
    Zhonghua Gan Zang Bing Za Zhi; 2002 Feb; 10(1):64. PubMed ID: 11856509
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.